Durability

The year-10 question

Oscar clears the framework's revenue-decline disqualifier: total revenue compounded from $488 million in 2019 [1] to $11.7 billion in 2025 [2] with no back-to-back down year. The conviction sources behind that growth are thinner. Approximately 98% of revenue sits inside one federal statute [3], 93% of premiums arrive from one payer and every carrier elects participation annually [4], and the operating record runs 14 years against a $3,294.4 million accumulated deficit [5].

Where the conviction would have to come from

The framework's year-10 gate does not ask whether a business is growing. It asks what would keep revenue and adjusted free cash flow higher a decade out even if management changed, competitors attacked, and the cycle turned. Five sources supply that: market structure, regulatory entry barriers, capital intensity, essentialness, and operating history. Each is tested below against Oscar's own record rather than against the sector's reputation.

Sources: FY2025 Annual Report (Form 10-K), Item 1 Business and Item 1A Risk Factors [6], [7], [8], Note 16 Statutory Regulations [9] and the loss-history risk factor [10].

Market structure

Oscar names its own competitive set: "plans offered by national carriers, regional carriers, Medicaid-focused insurers offering Health Insurance Marketplaces products, and local Blue Cross plans" [11]. That is four categories of rival, not a duopoly. Page 8 states the participation rule plainly: "We elect to participate in a given individual market on an annual basis" [12]. Participation is an annual election for every carrier in the market, Oscar included. There is no franchise, no licence scarcity, no installed base that has to be replicated.

The share record confirms what that structure implies. At the 2021 IPO, Oscar reported "an estimated 10% market share across the counties we serve in the Individual market" and described itself as the third largest for-profit national insurer in the segment [13]. In February 2026 management reported that "Oscar's market share across our footprint increased from 17% in 2025 to 30% in 2026" [14]. A 13-point share move inside twelve months is the opposite of the stability the gate looks for. It reads as a gain now; the same mechanism prices it back out when the carriers who withdrew return. Management attributes the gain directly to that withdrawal: it went after growth "as competitors pulled back or exited the market" [15].

Sources: FY2021 10-K [16]; FY2022 10-K [17]; FY2023 10-K [18]; FY2024 10-K [19]; FY2025 10-K [20]; Q4 FY2025 call for the February 2026 figure [21]. Footprint share is management's own measure and is reported only for 2020, 2025 and 2026.

The 2023 dip is worth reading closely. Membership fell 10%, and the filing explains why: "we requested that regulators limit our membership growth in Florida above a certain threshold so that total membership across all markets would be within our previously announced target range of 900,000 to 1,100,000" [22]. Oscar had to ask a regulator to cap its own growth because it could not fund the statutory capital. That is capital intensity acting as a brake, not as a wall against rivals.

Regulatory entry barriers

The barrier is real and specific. To sell insurance in a jurisdiction a carrier "must establish an adequate provider network and demonstrate our ability to perform or delegate utilization management and other administrative functions", and Marketplace participation carries "in some cases an annual recertification process" [23]. State solvency regimes add minimum statutory capital and restrictions on dividends up to the parent [24].

What the regime blocks is a garage startup. What it does not block is Centene, Elevance, UnitedHealth, Cigna, Molina and every Blue licensee, all of whom already hold the licences, the networks and the surplus. Oscar is itself the proof that the barrier is passable: a company founded in 2012 [25] reached roughly 2.0 million members by 2025 without owning a single structural asset the incumbents lacked. The framework's bank-and-insurer barrier argument works when the regulator's protection is asymmetric in the incumbent's favour. Here it is symmetric among the carriers who matter.

Capital intensity

Aggregate statutory capital and surplus across the Health Insurance Subsidiaries was approximately $1.0 billion at 31 December 2025, against $1.2 billion a year earlier [26]. Set against $11.7 billion of revenue, that is a regulatory reserve, not a replacement-cost moat. Nothing here resembles a network, a right-of-way, a licence area or an asset base a challenger would have to spend a decade rebuilding. The capital requirement rises with membership rather than falling with scale: the filing warns that growth "could trigger further increased capital requirements, including RBC, that could substantially exceed the net income generated by the health plan or in the new market" [27]. This conviction source does not apply.

Essentialness

Health coverage is essential. Subsidised individual coverage bought on an exchange is a policy construct, and the two are not the same claim. During 2025 approximately 97% of Oscar's direct policy premiums were subsidised by advance premium tax credits, up from 92% in 2024 [28]. The demand is real; its price to the member is set by Congress.

There is a genuine countercyclical argument on the other side, and it should be stated. When employer coverage or Medicaid falls away, the individual market absorbs the lives: Oscar's 2024 growth was driven partly by special enrollment following Medicaid redeterminations, and management frames the current inflow as entrepreneurs, gig workers, part-time employees and early retirees for whom group insurance no longer works [29]. Demand for the category through a recession is plausibly stable or better. Demand for Oscar's share of it is a separate question, and the annual-election structure answers it unfavourably.

Operating history

"The year ended December 31, 2024 was the first time since our inception in 2012 that we achieved profitability on either a consolidated net income or Adjusted EBITDA basis." Oscar did not repeat it in 2025, and the accumulated deficit stood at $3,294.4 million at year-end [30]. Fourteen years of operating history, one profitable year in it, against a framework reference of 30 to 50 years and survival through cycles. The ACA Marketplace itself has existed only since 2014 and has never been through a US recession in its present form.

The structural threats

Regulatory reversal, already delivered

This is not a hypothetical. Approximately 98% of Oscar's revenue in both 2025 and 2024 "was derived from sales of health plans subject to regulation under the ACA" [31]. The enhanced advance premium tax credits that lifted marketplace enrollment from 2021 "expired at the end of 2025 and the pre-ARPA APTC structure has been reinstated" [32]. Separately, the One Big Beautiful Bill Act signed on 4 July 2025 limits APTC eligibility for certain populations, and CMS program-integrity rules issued 25 June 2025 tighten eligibility verification, shorten open enrollment and suspend certain special enrollment periods, with several provisions under a nationwide court stay [33].

The size of the sensitivity is now observable rather than modelled. Management's own planning range was a 20% to 30% contraction of the individual market on subsidy expiry, and it priced 2026 at the high end of that range [34]. Congress did not extend the credits: they lapsed at the end of 2025 and the pre-ARPA structure took their place [35]. Measured on effectuation rather than plan selections, management put the contraction at 5% as of February and expected the reduction to reach the lower end of that 20% to 30% range by year-end [36].

For the year-10 question the number that matters is not the contraction itself but what it demonstrates: a single expiring tax provision removed on the order of a fifth to a quarter of Oscar's entire addressable market in one enrollment cycle, with no change in the product, the technology or the competition. That provision is reset by Congress each session, in both directions. A business whose addressable market can move 20% on a legislative calendar does not have a year-10 revenue floor that can be underwritten with very high conviction.

Customer concentration

"For the year ended December 31, 2025, 93% of premiums were earned directly from CMS and 7% were from our members" [37]. Ninety-three per cent of cash receipts come from one counterparty, which is also the regulator, the rule-writer and the party that sets the subsidy. Concentration on the cost side is milder but present: AdventHealth, HCA Healthcare and Baptist Health South Florida together took approximately 24% of total allowable medical costs in 2025 [38].

Competitive re-entry

The 13-point footprint share gain came as competitors pulled back or exited the market, on management's own account [39]. Centene, the largest carrier in the market, described itself as serving 5.5 million Marketplace members across 29 states at 31 December 2025 [40] and told investors six weeks later it expected roughly 3.5 million by the end of the first quarter of 2026, down from about 5.0 million in December [41]. The market did not consolidate around a protected position; it shrank and reshuffled, and Oscar reshuffled into the gap.

Quantifying the reversal is straightforward because the arithmetic is symmetric. Oscar guides to $18.7 billion to $19.0 billion of 2026 revenue [42], roughly 61% above 2025, on a footprint share of 30% against 17%. If footprint share reverted to the 2025 level as withdrawn carriers returned, and premium rates held, the same footprint would support revenue on the order of $10.6 billion to $10.8 billion — below 2025's $11.7 billion, and reached without any deterioration in Oscar's execution. That is the year-10 exposure in one line: a plausible 43% revenue reduction from a competitive event that requires nothing more than rivals filing rates.

Substitution, technology, and the margin question

Nothing in the record — Oscar's filings, the transcripts, or the peer disclosure — names a technology that makes Oscar's product obsolete. Nobody is disintermediating the ACA risk pool; the plan has to be underwritten by a licensed carrier. Two adjacent points do matter.

The first is that Oscar's own differentiators are not defensible in the framework's sense. The +Oscar technology platform serves nearly 0.6 million client lives on Campaign Builder, against roughly 2.0 million insurance members [43], and the ICHRA thesis Oscar has built its growth case on appears verbatim in Centene's filing as its own opportunity [44]. Lower administrative cost from automation is a real advantage and a genuine one; it is also execution, and execution carries no year-10 protection.

The second cuts the other way, and is the strongest structural point in Oscar's favour. The ACA's minimum medical loss ratio provision requires insurers to rebate to members when medical costs fall below the specified threshold [45]. Underwriting margin in this market is capped by statute, so there is no fat margin here for a new entrant to attack. The answer to "is anyone's margin an opportunity" is largely no, because the regulator already took it. The corollary is that the same rule caps Oscar's own margin compounding, which is why the year-10 free-cash-flow question turns on volume rather than price.

Risk adjustment as a recurring drag

The federal risk-adjustment programme is a zero-sum transfer between carriers in each state. Oscar has been a substantial net payer: risk transfer ran approximately 18.5% of direct premiums in 2025, up 390 basis points year on year [46], and the net risk adjustment payable rose from $1,493.6 million to $2,531.6 million during 2025 [47]. Because Oscar attracts a younger, healthier book than the market average, it pays into the pool structurally rather than episodically. That is not a threat to survival, but it permanently removes roughly a fifth of gross premium from the revenue line and makes the reported figure dependent on an estimate that CMS does not settle until June of the following year [48].

The disqualifier check

The framework disqualifies a company whose revenue has declined at a high-single-digit rate for three consecutive fiscal years after a long existence. fit_features.revenue_trajectory records consecutive_decline_years: 0 and three_year_hsd_decline: false. The flag does not fire.

The feature file's underlying series requires a correction. Its revenue values are Oscar's "Other revenues" line, not total revenue: $28.6 million for 2025, $20.6 million for 2024, $21.4 million for 2023 and $64.9 million for 2022 match the filed "Services and other" and "Administrative services revenue" figures exactly [49], and that line is defined in the filing as brokerage, enrollment-platform, market-education, +Oscar platform, virtual-card rebate and sublease income [50]. Total revenue for the same years was $11,701.4 million, $9,177.6 million, $5,862.9 million and $3,963.6 million [51]. The flag reaches the right answer on the wrong series; both series are shown below so the reader can check it either way.

Source: fit_features.revenue_trajectory, reproduced exactly as computed. The series corresponds to the filed Other revenues line, not total revenue [52], as reported in the Consolidated Statements of Operations [53].

Sources: FY2021 10-K, Consolidated Statements of Operations [54]; FY2023 10-K, Consolidated Statements of Operations [55]; FY2025 10-K, Results of Operations [56].

On the filed numbers there is one down year in seven, 2020 at $462.8 million against $488.2 million in 2019, a 5.2% decline caused by a change in ceded reinsurance rather than by lost business [57]. No consecutive declines, and nothing close to the three-year high-single-digit pattern. Structural decline is checked and absent. Oscar is a growing business inside a market that has just contracted, which is a different condition and is treated as such above.

FCF consistency

fit_features.fcf_stability returns an empty rolling series and not_computable with the reason "fewer than five consecutive adjusted-FCF years"; fit_features.adjusted_fcf is likewise empty, because the structured cash-flow feed carries operating cash flow but not capital expenditure, stock-based compensation or acquisitions. The framework's consistency test cannot be run from the deterministic file. It can be run from the filings, and the result is more informative than a gap line, so it is set out here with its workings and labelled as a derivation rather than a feature.

All figures $ millions. Adjusted FCF = operating cash flow − capital expenditure − stock-based compensation; no acquisition line is disclosed in the cash-flow statements for these years, so the framework's five-year average acquisition deduction is zero. Derived from the Consolidated Statements of Cash Flows in the FY2022 [58], FY2023 [59] and FY2025 [60] 10-Ks.

Source: derived from the Consolidated Statements of Cash Flows, FY2022 to FY2025 10-Ks [61].

Three readings come out of that table.

Two of the six years are negative, and the swing runs from −$457.4 million in 2023 to +$970.8 million in 2025. Only two consecutive positive years exist in the whole record, 2024 and 2025. The rolling five-year average — the framework's actual test — can be computed for exactly two windows: FY2020 to FY2024 averages $100.2 million, FY2021 to FY2025 averages $259.8 million. A 159% move between two adjacent rolling windows is the definition of an unstable base, and two windows is too few to call it anything else.

The composition matters more than the level. In 2025 the increase in the risk adjustment transfer payable was $1,029.4 million against operating cash flow of $1,094.9 million [62]. Essentially the entire year's operating cash flow was money owed to CMS and not yet paid. Oscar paid $1,611.7 million of prior-year risk transfers during 2025 and closed the year owing $2,587.7 million gross [63]. Strip that single line out and adjusted free cash flow is negative in five of six years and cumulatively −$817 million over 2020 to 2025.

The fair counter is that this is float, and float is a legitimate feature of an insurer's cash generation: a carrier whose premium base grows holds a permanently larger payable, so the build is not purely a borrowing. The honest boundary is that the risk-adjustment payable is settled in cash roughly a year in arrears against a CMS report received each June [64], so it recurs as a net benefit only while premiums keep growing. The first quarter of 2026 shows the same pattern at a larger scale, $2,619.0 million of operating cash flow on $679.0 million of net income [65]. Cash generation here is a function of growth, not a separable property of the business.

On the framework's own carve-out — an occasional negative episode every five to eight years is healthy in insurance and banking, because it is the price of the good years — the pattern does not fit. The negative years are 2021 and 2023, two years apart, and the loss years are 2019 through 2023 plus 2025. That is not an underwriting cycle around a stable base; it is a company that reached a positive base for the first time in 2024 and has not yet held it for three consecutive years. The mechanism is also different: 2025's loss came from a market-wide morbidity misestimate and the resulting risk adjustment true-up [66], which is a forecasting error of the kind the framework treats as temporary and is examined in Damage Math, not a scheduled underwriting downturn.

The year-10 case, both ways

The strongest case that year-10 revenue and adjusted FCF are higher

The individual market did not collapse when the enhanced credits expired. CMS data cited by management showed roughly 23 million lives at the 2026 open enrollment, a 5% decline against a record 24 million in 2025 rather than the feared quarter [67], [68], [69], and by April 2026 the interim Wakely data had contraction tracking at or better than the favourable end of management's 20% to 30% range [70]. Oscar grew through it: 3.2 million members at the end of the first quarter of 2026, up 56% year on year, and approximately 3 million paid members at 1 April [71]. Guidance is $18.7 billion to $19.0 billion of revenue and $250 million to $450 million of earnings from operations for 2026 [72].

The structural argument behind it is that employer coverage is migrating toward individual coverage, that ICHRA is the mechanism, and that the largest carrier dedicated exclusively to the individual market is the natural beneficiary. The category is essential, the underlying APTC structure survived the 2025 fight intact even as the enhancement lapsed, and the statutory minimum-MLR floor means no rival can attack Oscar's underwriting margin because there is no excess margin to take. Revenue ten years out on this reading is comfortably above $11.7 billion; adjusted free cash flow follows once the risk-adjustment position normalises and administrative leverage compounds.

The strongest doubt

Ninety-eight per cent of revenue depends on one statute, 93% of premium cash arrives from one payer, and the subsidy that determines whether the product is affordable is voted on by Congress. That variable moved once already, and management's own expectation is that it reduces the market by the lower end of a 20% to 30% range across 2026 [73]. The share position that carried Oscar through it — 17% of footprint to 30% — was handed over by carriers who exited, and every one of them can re-file rates for any plan year, because as the filing puts it, "We elect to participate in a given individual market on an annual basis." Reversion to the 2025 footprint share at current rates puts revenue near $10.6 billion to $10.8 billion, below 2025, without any operating failure at Oscar. Underneath that, adjusted free cash flow has been positive in four of six years, has never held a positive five-year base, and in 2025 was $970.8 million only because $1,029.4 million of money owed to CMS had not yet been paid.

The read

The gate is not met. Year-10 revenue and adjusted free cash flow being higher than today's requires very high conviction, and the record supplies genuine doubt from three independent directions: a single legislated demand driver that has already been cut once, a market position taken by annual election rather than held by structure, and a cash-flow series with no stable base and no five-year history to average. The strongest fact against this read is that Oscar has just grown revenue 61% and membership 56% straight through the exact shock the doubt is built on, which is real evidence that the business is more resilient than the concentration figures alone imply. It does not close the gap, because the growth came from share taken out of a shrinking market rather than from anything that would stop a rival taking it back. What would change the read: three to four consecutive years of positive adjusted free cash flow measured without the risk-adjustment payable build, footprint share holding above 25% through a plan year in which two or more of the withdrawn national carriers re-file, and a permanent statutory subsidy structure that no longer expires on a schedule.

The yield arithmetic (Yield) and the capital-allocation record (Self-Help) are scaled tests; this gate sits ahead of them by the framework's own construction.